CS
MCRB icon

Credit Suisse’s Seres Therapeutics MCRB Stock Holding History

Credit Suisse’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6,869
Closed -$327K – 3112
2023
Q3 		$327K Sell
6,869
-1,670
-20% -$127K ﹤0.01% 2901
2023
Q2 		$818K Buy
8,539
+2,399
+39% +$261K ﹤0.01% 2526
2023
Q1 		$696K Buy
6,140
+2
+0% +$216 ﹤0.01% 2541
2022
Q4 		$687K Buy
6,138
+307
+5% +$41.2K ﹤0.01% 2586
2022
Q3 		$749K Buy
5,831
+1,313
+29% +$134K ﹤0.01% 2531
2022
Q2 		$309K Buy
4,518
+177
+4% +$15.2K ﹤0.01% 3145
2022
Q1 		$618K Buy
4,341
+188
+5% +$28.9K ﹤0.01% 2847
2021
Q4 		$692K Buy
4,153
+1,830
+79% +$291K ﹤0.01% 3594
2021
Q3 		$323K Buy
2,323
+182
+9% +$35.6K ﹤0.01% 4057
2021
Q2 		$1.02M Sell
2,141
-255
-11% -$108K ﹤0.01% 3369
2021
Q1 		$987K Sell
2,396
-3,430
-59% -$1.58M ﹤0.01% 3334
2020
Q4 		$2.85M Buy
+5,826
New +$3.41M ﹤0.01% 2566
2018
Q2 		– Sell
-704
Closed -$103K – 4080
2018
Q1 		$103K Buy
704
+180
+34% +$34.5K ﹤0.01% 3796
2017
Q4 		$106K Sell
524
-519
-50% -$107K ﹤0.01% 3833
2017
Q3 		$334K Buy
1,043
+480
+85% +$131K ﹤0.01% 3690
2017
Q2 		$127K Buy
+563
New +$116K ﹤0.01% 3700
2017
Q1 		– Sell
-1,405
Closed -$279K – 3966
2016
Q4 		$279K Buy
1,405
+118
+9% +$25.7K ﹤0.01% 3691
2016
Q3 		$317K Buy
1,287
+487
+61% +$171K ﹤0.01% 3635
2016
Q2 		$465K Buy
800
+320
+67% +$188K ﹤0.01% 3468
2016
Q1 		$254K Buy
480
+48
+11% +$25.1K ﹤0.01% 3589
2015
Q4 		$303K Sell
432
-1,027
-70% -$675K ﹤0.01% 3681
2015
Q3 		$865K Buy
+1,459
New +$1.19M ﹤0.01% 2939

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse's MCRB Position: Q4 2023 in Review

Credit Suisse sold out of Seres Therapeutics (MCRB) in Q4 2023, closing a stake of 6,869 shares — an estimated $327K sold.

Credit Suisse first reported a position in MCRB in Q3 2015 and held it in 22 quarters. The position peaked at $2.85M in Q4 2020. 102 funds tracked by Wall St. Rank hold MCRB as of Q4 2023.

  • Credit Suisse reported no remaining Seres Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Credit Suisse sold 6,869 Seres Therapeutics shares in Q4 2023, an estimated $327K.
  • Credit Suisse first reported a position in Seres Therapeutics in Q3 2015 and held it in 22 quarters.
  • Credit Suisse's Seres Therapeutics position peaked at $2.85M in Q4 2020.
  • 102 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2023.

Based on Credit Suisse's 13F filing for Q4 2023, filed 8 Feb 2024.